Biotechnology
WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership
* Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER[1] basis (41.5% growth on a CER[2] basis) * Gross profit grew by 40.6% period-over-period, reaching RMB 1,371.3 million. Gross profit margin was 37.0%, a 0.9 percentage points increas...
2026-08-24 20:35
590
Peijia Medical Announces 2026 Interim Results, Achieving First-Ever Profit Before Tax on Strong TAVR Growth
SUZHOU, China, Aug. 24, 2026 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced its interim results for the six months ended June 30, 2026 (the "Reporting Period") on ...
2026-08-24 20:00
708
ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"
* Development of Leptin receptor-based technology and hybrid LNP platform * Combining Blood-Brain Barrier penetration and a one-month sustained-release formulation in a single structure, with potential applications in CNS-targeted therapeutics * Technology validated by winning first place in...
2026-08-24 15:01
544
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
* HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including obesity * Total deal value of up to $2.3 billion, including upfront, milestone payments and tiered royalties based on net sales SEOUL, South...
2026-08-24 12:40
503
Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease
NEW YORK, Aug. 23, 2026 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), today announced the enrollment of the first two patients in its PULSE-LHD clinical trial, conducted under a U.S. Food and Drug Administ...
2026-08-24 11:05
638
Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics
SEONGNAM, South Korea, Aug. 23, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Lilly Gateway Labs is a best-in-class innov...
2026-08-24 09:54
671
CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed in-house, in Australia. Subject enrollment is progressing smoothly. CG-0416 is designed based o...
2026-08-21 20:08
4926
China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"?
BEIJING, Aug. 21, 2026 /PRNewswire/ -- Personalized mRNA cancer therapy has recently reached an important milestone. An international Phase 3 study in high-risk melanoma reported positive results, further supporting the clinical potential of personalized neoantigen therapy and drawing renewed att...
2026-08-21 17:28
977
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
NANJING, China, Aug. 21, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Op...
2026-08-21 17:20
1226
Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the latest clinical data on its novel epidermal growth factor receptor (EGFR) inhibitor ZE...
2026-08-21 16:03
1169
Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's Nat...
2026-08-21 13:30
1460
Matwings Demonstrates Closed-Loop Protein AI Through Four AI-Wet Lab Cycles and 222 Protein Variants
The GenSci148 program illustrates a shift from one-time mutation prediction to iterative protein engineering under real drug-development constraints SHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Shanghai Matwings Technology Co., Ltd. ("Matwings") today announced that GenSci148 Injection, an investigati...
2026-08-20 19:00
886
Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum
SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first half of 2026. During the reporting period, innovative drugs remained the Company's key growth driver, while globalization initiatives continued to validate the g...
2026-08-19 19:46
1287
NORROY BIOSCIENCE Granted FDA Breakthrough Therapy and Fast Track Designations for Kidney Cancer Imaging Product
WUXI, China, Aug. 19, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations to NORRO...
2026-08-19 17:00
1065
CARsgen Therapeutics Announces 2026 Interim Results
SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results. Business Highlights * Cash and cash equivalents were around RMB1,400 million as of June ...
2026-08-19 08:15
1909
Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
* Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. * Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics develo...
2026-08-19 03:44
1333
Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...
2026-08-18 17:02
1306
WuXi XDC Achieves GMP Release of BCM3 Facility at Singapore Site, Enabling Global Clients with Professional Excellence
SINGAPORE, Aug. 18, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that its BCM3 dual-function production line for antibody i...
2026-08-18 12:03
2523
Enginprime Medical Closes $12M Series A Financing
Round exclusively led by Qiming Venture Partners; proceeds to fund China registration trial and overseas early-stage clinical development SHANGHAI and HANGZHOU, China, Aug. 17, 2026 /PRNewswire/ -- Enginprime Medical ("Enginprime" or the "Company"), a developer of percutaneous ventricular assist...
2026-08-18 08:00
2384
Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths
CAMBRIDGE, Mass., Aug. 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in MSCI Global Small Cap Indexes compiled by Morgan Stanley Capital Internatio...
2026-08-17 20:30
3649
Week's Top Stories
Most Reposted
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
[Picked up by 299 media titles]
2026-08-24 10:00
Traveloka SEA Index Q2 2026: Southeast Asians Are Booking Longer Stays and the Region's Own Beaches Are Winning
[Picked up by 288 media titles]
2026-08-18 09:00
OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
[Picked up by 287 media titles]
2026-08-24 15:42
Miss World 2026 at Dragon Ocean Do Son: Elevating Vietnam's destination profile on the global stage
[Picked up by 283 media titles]
2026-08-19 17:43
2026 Taiwan Jewellery & Gem Fair to Take Place in November
[Picked up by 273 media titles]
2026-08-24 15:30
Most Read
Traveloka SEA Index Q2 2026: Southeast Asians Are Booking Longer Stays and the Region's Own Beaches Are Winning
2026-08-18 09:00
9338
Miss World 2026 at Dragon Ocean Do Son: Elevating Vietnam's destination profile on the global stage
2026-08-19 17:43
5010